StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$28.46−2.21 (-7.21%)

Close on Nov 20, 2026Market cap $334.51MP/E –Yield –

Surrozen free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Surrozen's free cash flow for the twelve months ending Jun 30, 2026 was -$34.98M. For fiscal 2025 it was -$30.37M. The highest annual figure on record is -$17.65M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$30.37M–
FY2024Dec 31, 2024-$17.65M–
FY2023Dec 31, 2023-$40.76M–
FY2022Dec 31, 2022-$44.87M–
FY2021Dec 31, 2021-$50.08M–
FY2020Dec 31, 2020-$29.97M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.43M–
Q1 FY2026Mar 31, 2026-$12.62M–
Q4 FY2025Dec 31, 2025-$5.87M-269.6%
Q3 FY2025Sep 30, 2025-$9.06M–
Q2 FY2025Jun 30, 2025-$6.13M–
Q1 FY2025Mar 31, 2025-$9.31M–
Q4 FY2024Dec 31, 2024$3.46M–
Q3 FY2024Sep 30, 2024-$6.75M–
Q4 FY2023Dec 31, 2023-$7.31M–
Q3 FY2023Sep 30, 2023-$10.13M–
Q2 FY2023Jun 30, 2023-$8.83M–
Q1 FY2023Mar 31, 2023-$14.49M–
Q4 FY2022Dec 31, 2022-$353.00K–
Q3 FY2022Sep 30, 2022-$14.30M–
Q2 FY2022Jun 30, 2022-$11.44M–
Q1 FY2022Mar 31, 2022-$18.79M–
Q4 FY2021Dec 31, 2021-$11.87M–
Q3 FY2021Sep 30, 2021-$14.60M–
Q2 FY2021Jun 30, 2021-$12.94M–
Q1 FY2021Mar 31, 2021-$10.68M–
Q4 FY2020Dec 31, 2020-$9.80M–

More Surrozen figures

See a number that looks wrong?